USF Health’s IDPodcasts

Dr. Jackie Sherbuk, Assistant Professor of Medicine at the USF Morsani College of Medicine, presents this case-based review of the opportunistic infectious syndromes associated with HIV-AIDS. The speaker covers PJP prophylaxis and treatment, HIV pulmonary disease, and cryptococcal meningitis. Dr. Sherbuk also discusses IRIS (Immune Response Inflammatory Syndrome) and its effect on the AIDS patient when antiretrovirals are started. Lastly, Dr. Sherbuk covers HIV esophageal disorders, Histoplasmosis, Coccidioidomycosis, and Mycobacterium avian-complex-related syndromes.

Dr. Jackie Sherbuk, Assistant Professor of Medicine at the Morsani College of Medicine Division of Infectious Diseases, presents this case-based review of the use of antiretroviral therapy in HIV/AIDS patients. Dr. Sherbuk begins by reviewing and available antireturovial options, including those that are considered first line. She also covers the use of antiretrovirals in special groups, including expectant mothers, elite controllers, treatment experienced patients, HBV/HIV connected patients, and patients with chronic renal insufficiency. Lastly, Dr. Sherbuk discusses the nuances of using co-formulated combinations of antiretrovirals and mentions the newer long-acting injectable preparations.

Dr. Jamie Morano, Infectious Diseases and HIV Specialist with the University of South Florida College of medicine, presents an overview of the diagnosis and management of HIV infection. Part of USF ID’s Basics of HIV Management Review Series.

Pharmacotherapy specialist Kristin Zeitler, PharmD, from Tampa General Hospital in Tampa, FL, presents this talk on the basics of antimicrobial therapy management for hospital patients. Dr. Zeitler begins by emphasizing the important of the ID clinical pharmacist. She then compares and contrasts Pharmacokinetics (PK) , the way drugs move through the body, with Pharmacodynamics (PD), the relationship between serum drug concentration and the therapeutic/toxic effects of the drug. PK/PD effects of antimicrobials are then further explored. Dr. Zeitler goes on to discuss Vancomycin dosing strategies, the effects of serum albumin on serum antimicrobial drug levels, drug penetration into the site of interest, drug dosing strategies for patients with renal insufficiency, and the effects of obesity and critical illness on antimicrobial dosing strategies.

Dr. Shylah Moore-Pardo, Infectious Diseases clinician and Assistant Professor at the University of South Florida, reviews antiretroviral initiation in HIV positive patients. In a case-based format, Dr. Pardo begins by discussing the interpretation of HIV test results. Next, she highlights several unique positive test scenarios. Dr. Pardo then reviews the characteristic serological patterns of acute HIV infection. The impact of False Positive HIV testing is also explained. Also covered are patients known as elite-controllers and long-term non-progressers who are more tolerant of HIV infection. Dr. Pardo then goes on to describe essential components of the initial HIV positive patient encounter. She then relates recommended test and treat strategies compatible with current guidelines. Lastly, she covers the next steps in management for future patient visits.

Dr. Jose Montero, Medical Director of the Antibiotic Stewardship Program at Tampa General Hospital, presents a basic review of the use of antibiotics in infectious diseases for 2024. Dr. Montero reviews the different classes of antibiotics used in the hospital setting. He then covers each agent’s mechanisms of action, spectrum of activity and common indications. He also mentions the most common adverse reactions associated with antibiotic agents. Classes of agents covered include the penicillin agents, cephalosporins, carbapenems, fluoroquinolones, macrolides, aminoglycosides, glycopeptides, oxazolidinones, glycylcyclines, and beta-lactam-beta-lactamase inhibitor combinations. Lastly, Dr. Montero reviews emerging new agents on the horizon.

Melissa Albert, Infectious Diseases Pharmacist at the James A Haley Veterans Hospital, discusses the recent new literature regarding changes in the clinical breakpoints. Utilizing clinical cases, Dr. Albert demonstrates how to interpret antimicrobial susceptibility reports as well as how to design a patient-centered treatment regimen. Dr. Albert also discusses inducible AmpC-E resistance and how specific breakpoints have been changed for Aminoglycosides. From a lecture originally presented in March 2024.

Dr. Shylah Moore-Pardo, Assistant Professor with the Division of Infectious Diseases and International Medicine, reviews the basics regarding vaccinations in the HIV-positive population. Dr. Pardo first reviews routine immunizations, such as Influenza, Tetanus, and COVID-19. She then covers risk specific vaccines, such as shots for Hepatitis B and C, meningococcus, and Mpox. Next, Dr. Pardo discusses routine vaccines indicated based upon one’s age, including Shingles, HPV, and pneumococcus. She then reviews non-routine vaccines given as indicated (Rabies, Men-B, Travel vaccines, etc.). Lastly, in a question and answer format, Dr. Pardo goes over common vaccine-oriented board questions and provides explanations and context as to the answers to those questions. From a lecture originally presented in January 2024.

Dr. Lauren Rybolt, Infectious Diseases Fellow at the Division of Infectious Diseases, Morsani College of Medicine, discusses the ways that climate change is expected to alter the infectious diseases landscape. Dr. Rybolt begins her talk with the discussion of vector-borne diseases, and then goes on to discuss zoonotic infections, water-borne diseases, habitat changes, and natural disaster impacts. Lastly, Dr. Rybolt completes her talk by sharing information on climate change solutions and adaptations.

Dr. Guy Handley, Assistant Professor of Medicine with the Division of Infectious Diseases, USF Morsani College of Medicine, provides an overview of Human Herpesvirus 6 in Stem Cell Transplant Patients. Dr. Handley uses clinical cases to describe several scenarios related to HHV6 infection. Topics discussed include background, HHV6 latency, reactivation, clinical presentation, encephalitis, treatment strategies, and outcomes. Guidelines for HHV care are also discussed. Dr. Handley closes by discussing controversies and future directions in HHV6 management.